To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with JavaScript enabled.
This website is not optimized for your browser, as configured.

Driving Progress Against Childhood Cancer

Childhood cancer is rare, yet about 11,050 children in the United States under the age of 15 will be diagnosed with cancer in 2020. While many types of cancers can appear in people of all ages, we know that kids are not just little adults and treatment often needs to be different. Pediatric clinical trials allow for the development of medicines with the unique needs of children in mind and have helped drive great strides against childhood cancer (1). Yet, there is still much more to learn and new advancements to be made.

Currently Lilly is working on an innovative approach to support advancing pediatric research by using master protocols to study new treatments for cancer patients. Master protocols are a novel way to study multiple research questions about several different drugs, diseases or conditions all in one clinical trial (instead of having to have multiple clinical trials) (2). Some of the potential benefits of this approach are to help to quickly test and answer scientific questions, compare different treatment options, reduce the cost of the study, reduce the time to set up new studies or enroll patients to aid in our ability to create medicines for our pediatric cancer patient population faster than we normally would under a non-master protocol clinical trial. 

An example of some of our master protocol clinical trials in pediatrics can be found at with the heading in the title of the study "CAMPFIRE." CAMPFIRE stands for "Children’s and Young Adult Master Protocol for Innovative Pediatric Research." CAMPFIRE is a platform to accelerate the development of novel treatments for pediatric and young adult patients with cancer. This platform uses innovative designs and an overarching infrastructure to harness the benefits of shared data and operational efficiencies. The investigational agents on the trial will change over time based on the criteria established in the sub-protocols.

Explore the infographic below to learn more about the landscape of childhood cancer and the role of pediatric research in powering progress.

DrivingProgressAgainstChildhoodCancer Infographic 2Mar2020-01


  2. J. Woodcock, L.M. LaVange. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med., 377 (2017), pp. 62-70

Blog post originally appeared on LillyPad.

Tags: Cancer, Infographic, Pediatric Research,

Recent Articles

From Alzheimer’s Diagnosis to Advocate

LTGBlogAuthors GuestAuthorIcon 20July2018
Guest Author
January 31st, 20225 minute read

Geri had been involved in research in addition to having a healthcare background. Because of this, after being diagnosed with Alzheimer's she knew that she wanted to participate in a clinical trial.

Committed to Cancer Research

Leigh Anne Naas Headshot
Leigh Anne Naas
September 24th, 20211 minute read

Lilly has a strong legacy in cancer research. Our dedicated oncology team work together to create medicines that make life better for people around the world.

Proud Partners in Breast Cancer Research

Leigh Anne Naas Headshot
Leigh Anne Naas
September 22nd, 20213 minute read

Lilly is proud to foster true partnerships with external stakeholders. By working together to raise awareness of breast cancer research, we can make life better for people around the world.

Recommendations for Decentralized Clinical Trial Capabilities in the Wake of COVID-19

Kevin Hudziak
September 15th, 20214 minute read

Tips to implement an effective and successful decentralized clinical trial for multiple touch points.

The COVID-19 Pandemic Changed How Sites Conduct Clinical Trials Forever

Kevin Hudziak
July 29th, 20213 minute read

To better understand how various countries adapted to execute clinical trials during a pandemic, we conducted a series of virtual feedback sessions with clinicians from all over the world.

This site is intended for US residents.
This site is intended for US residents.